drugset / Trial / NCT01493921
Efficacy Study & Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment
RandomizedParallel-groupTriple-blindTreatment
Summary
Studies of SR-T100 gel and its clinical relevance in the treatment of AK, providing adequate measured outcomes for skin lesion treatment. In addition to the high complete response rate (90.0%) as compared with the conventional therapy, the most significant result was that no undesirable side effects were associated with the use of SR-T100 gel. The result also shows approximately 80% of study subjects had a complete response in phase II clinical trial conducted in Taiwan; hence, result from our study model suggested SR-T100 gel offers beneficial therapeutic values in treatment of AK is harmless to the skin as well as high tolerance level displayed by majority of patients.
Timeline
- Start
- 2011-10
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SR-T100 | Unknown | 0.3 g | Topical |
| Subject | SR-T100 | Unknown | 0.5 g | Topical |